Is Market Sentiment Getting Behind This Emerging Small-Cap Specialty Syringe Medical Device Company?

The medical device and supply manufacturing industry is focused on the design and production of medical instruments and devices. As innovation and demand for medical devices increase, the market for this industry, which is currently worth approximately $99 billion, is very likely to  grow. However, it looks like the rising tide isn’t lifting all boats equally. It has been reported that the market is rallying behind some leaders in the industry, but not others. One of the reported rising companies is Sharps Technology STSS.

A specialty syringe developer and manufacturer which has a market cap of just $15 million, Sharps is a company in the space that seems to be poised for growth and is receiving positive investor sentiment. The specialty medical device company recently received a bullish sentiment stock reading from investing group InvestorsObserver

At the same time, a number of other medical device companies have seemingly received underperforming commentary or are within the feeling of market uncertainty and hesitancy, such as Becton Dickson and Co. BDX, Cardinal Health CAH,  and Terumo Corporation TRUMY.

Why is it that some medical device companies such as Sharps seem to have the support of market traders, while others don’t? There may be several contributing reasons.

Investment Groups are Giving Sharps Technology a Positive Outlook 

The forum scoreboard on shows Sharps Technology as having a 100% bullish sentiment rating from the forum’s users. Some traders on Stocktwits have also labeled Sharps’ stock as bullish. One trader cited the reduced capital needed to manufacture, as well as the reduced liability that comes with Sharps’ products, as reasons the company is well positioned in the market. Sharps has a wholly-owned 40K sq. ft manufacturing facility in Hungary with potential capacity of up to 200 million disposable syringe units in 2024, and through its collaboration with Nephron Pharmaceuticals (private), has potential capacity of up to 50 million units of prefillable syringe systems in South Carolina.

Retail investment outlet Simply Wall Street highlighted Sharps as having high growth potential, suggesting that the stock currently trades at 98% below its estimate of fair value. Meanwhile, another investment consultant praised the company for its manufacturing capacity capabilities. Manufacturing scalability potential, along with synergies through the partnership with Nephron, were mentioned as having strong potential to lead to growth in topline revenue.

A couple of recent announcements from Sharps may have also contributed to this seemingly bullish market sentiment. Sharps recently announced two significant progress updates with a press release on plans to introduce new specialized prefillable syringe systems in 2023, as well as shipping the first containers of syringes from its Hungary facility for commercialization.

Interested in learning more about Sharps Technology? Visit its website.

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Featured photo by Burak The Weekender on Pexels.

Market News and Data brought to you by Benzinga APIs
Posted In: BiotechPenny StocksHealth CareGeneralPartner ContentSharps Technology
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!